Summary
Ning Shen is a computational biologist and Principal Investigator with a PhD from Duke and over a decade of cross-sector experience translating genomics and machine learning into drug discovery insights. Based in Cambridge, MA, she has led computational programs from target identification to IND-enabling analyses, notably driving biomarker and cis-regulatory pipelines for muscular dystrophy programs at Fulcrum Therapeutics. At Harvard Medical School and Zhejiang University she combines academic rigor with industry pragmatism, mentoring teams and publishing translational work that bridges statistics, pharmacology, and wet-lab validation. Proficient in Python, R, Perl and cloud platforms (AWS/GCP), she builds reproducible analysis workflows (Git, Jupyter, R Markdown) to accelerate hypothesis-to-clinic timelines. Her background in dynamic network modeling and functional impact prediction gives her an edge in prioritizing variants and mechanisms often missed by standard pipelines. Colleagues describe her as an innovative scientific leader who pairs deep computational expertise with practical drug-development impact.
8 years of coding experience